Antibe Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.05.20	Antibe Therapeutics Updates Timing for Top-Line Results From Completed Phase 2B Dose-Ranging, Efficacy Study (Businesswire)
28.02.20	Antibe Therapeutics Announces Enrollment of Last Patient in Phase 2B Dose-ranging, Efficacy Study of Lead Drug, ATB-346 (Businesswire)
25.02.20	Antibe Therapeutics Provides Corporate Update and Reports Q3 2020 Interim Financial and Operating Results (Businesswire)
24.02.20	Antibe Therapeutics Announces Research Publication Demonstrating Markedly Enhanced Pain Relief and Increased Safety of Second Pipeline Drug (Businesswire)
21.02.20	Antibe Therapeutics Recognized as a TSX Venture 50 Company for Second Consecutive Year (Businesswire)
13.01.20	Antibe Therapeutics Expands Executive Team in Preparation for Large Market Partnering (Businesswire)
27.08.19	Antibe Therapeutics Provides Update on Phase 2B Dose-Ranging, Efficacy Study for ATB-346 (Businesswire)
26.07.19	Antibe Therapeutics Announces Size of Offering (Businesswire)
23.07.19	Antibe Therapeutics Announces Offering of Units (Businesswire)
17.07.19	Antibe Therapeutics Reports 2019 Year-End Financial and Operating Results (Businesswire)
03.07.19	Antibe Therapeutics Announces Results of Annual General and Special Meeting (Businesswire)
25.06.19	Antibe Therapeutics Announces CEO Letter to Shareholders (Businesswire)
03.06.19	Antibe Therapeutics Unveils Lead Indication for ATB-352, a Potent, Non-Addictive Analgesic for Severe Pain (Businesswire)
30.05.19	Antibe Therapeutics Announces Upcoming Conference Schedule (Businesswire)
16.04.19	Phase 2B GI Safety Results For ATB-346 Published in British Journal of Pharmacology (Businesswire)
29.03.19	Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346 (Businesswire)
04.02.19	Antibe Therapeutics Announces $5 Million Bought Deal Offering (Businesswire)
21.01.19	Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346 (Businesswire)
19.12.18	Antibe Therapeutics Raises $1.6 Million Through Warrant Exercises (Businesswire)
30.11.18	Antibe Therapeutics to Present at the 11th Annual LD Micro Main Event on December 4, 2018 (Businesswire)
27.11.18	Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346 (Businesswire)
22.10.18	Antibe Therapeutics Establishes Business Development Advisory Board (Businesswire)
10.10.18	Antibe Therapeutics Receives Approval to Initiate Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346 (Businesswire)
03.10.18	Antibe Therapeutics Announces Grant of Restricted Share Units (Businesswire)
05.09.18	Antibe Therapeutics Announces Strategic Licensing Deal for Lead Drug in South Korea (Businesswire)
30.08.18	Antibe Therapeutics Reports Q1 2019 Interim Financial and Operating Results (Businesswire)
31.07.18	Antibe Therapeutics Provides Clinical Development Update on Its Lead Drug (Businesswire)
07.07.18	Antibe Completes Share Issuance in Connection with Citagenix Credit Facility (Businesswire)
30.06.18	Antibe Therapeutics Reports 2018 Year-End Financial and Operating Results (Businesswire)
27.06.18	Antibe Therapeutics Announces Results of Annual General and Special Meeting (Businesswire)
29.05.18	Antibe’s Chief Scientific Officer to Present at 5th World Congress on Hydrogen Sulfide in Biology and Medicine (Businesswire)
24.05.18	Calgary Researchers Discover a Novel Approach to Treatment of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology (Businesswire)
30.04.18	Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference (Businesswire)
26.04.18	Antibe Therapeutics Announces CEO Letter to Shareholders (Businesswire)
03.04.18	Antibe Therapeutics Provides Financial Update (Businesswire)
20.03.18	Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346 (Businesswire)
13.03.18	Antibe Therapeutics Announces No Material Change (Businesswire)
28.02.18	Antibe Therapeutics Reports Q3 2018 Interim Financial and Operating Results (Businesswire)
26.02.18	Antibe Therapeutics Provides Update on Phase 2B Gastrointestinal Safety Study of Lead Pain Drug, ATB-346 (Businesswire)
29.01.18	Antibe Therapeutics Announces Enrollment of Final Subjects in Phase 2B Gastrointestinal Safety Study of Lead Pain Drug, ATB-346 (Businesswire)
17.01.18	Antibe Therapeutics Engages Brand Institute to Advise on Nonproprietary Name for ATB-346 (Businesswire)
29.11.17	Antibe Therapeutics Reports Q2 2018 Interim Financial and Operating Results and Provides Corporate Update (Businesswire)
20.10.17	Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions (Businesswire)
30.05.16	Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference (Businesswire)
08.11.13	Dr. John Wallace, Antibe Therapeutics Founder and Chief Science Officer, Awarded the Heymans Foundation Memorial Medal (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	79.18	1.64 %	K V
CieFinRichemont	140.20	1.26 %	K V
Swiss Re	132.30	0.92 %	K V
Swiss Life Hldg	707.40	0.91 %	K V
Zurich Insur Gr	529.40	0.80 %	K V
Roche Hldg G	263.40	-0.57 %	K V
Kuehne+Nagel Int	200.00	-0.65 %	K V
Novartis	90.11	-0.75 %	K V
Givaudan	3’848.00	-0.95 %	K V
Lonza Grp	537.40	-1.29 %	K V

Nachrichten zu Antibe Therapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten